PPARA and primary biliary cholangitis: MASLD/MASH and PBC are the primary focus of clinical trials with PPAR-agonists, since there is only one approved pharmacological treatment for MASLD/MASH and since PBC is also in need of secondary therapies for UDCA nonresponders.